Best-in-class splicing signal in DM1, a disease with no approved therapy, contingent on whether dose-escalation data translates to clinical function

Bull

A positive outcome would show robust, dose-dependent splicing correction meaningfully exceeding the 5 mg/kg cohort's ~22.9% (outlier-adjusted) result, accompanied by statistically and clinically meaningful improvement on vHOT or other functional endpoints versus placebo. This would confirm that the best-in-class Phase 1 splicing signal translates to multi-dose functional benefit, de-risking the registrational path and supporting the end-of-Phase 2 FDA meeting with a compelling efficacy and safety package.

Bear

The most likely failure modes are splicing correction that does not translate to functional improvement on vHOT (i.e., biomarker without clinical signal), an unacceptable safety signal such as persistent albuminuria or renal findings at higher doses, or data variability that makes the effect size ambiguous and insufficient to anchor a registrational dose. Additionally, if the FDA partial clinical hold on the U.S. portion is not resolved, it could limit the dataset and complicate regulatory discussions.